A pre-clinical study supports the potential for an acceptable therapeutic index with this inhibitor, as MK-2206 treatment was cytotoxic to primary pediatric T-ALL cells ex vivo without significantly affecting the viability of normal CD4+ peripheral T cells and CD34+ hematopoietic progenitor cells [49]. The gene discussed is CD34; the disease is acute lymphoblastic leukemia.